JPH0581567B2 - - Google Patents

Info

Publication number
JPH0581567B2
JPH0581567B2 JP60064081A JP6408185A JPH0581567B2 JP H0581567 B2 JPH0581567 B2 JP H0581567B2 JP 60064081 A JP60064081 A JP 60064081A JP 6408185 A JP6408185 A JP 6408185A JP H0581567 B2 JPH0581567 B2 JP H0581567B2
Authority
JP
Japan
Prior art keywords
temperature
preparing
aqueous phase
phase
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60064081A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60224617A (ja
Inventor
Rafuon Rui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon France SAS
Original Assignee
Laboratoire L Lafon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire L Lafon SA filed Critical Laboratoire L Lafon SA
Publication of JPS60224617A publication Critical patent/JPS60224617A/ja
Publication of JPH0581567B2 publication Critical patent/JPH0581567B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
JP60064081A 1984-03-30 1985-03-29 経口投与用の製剤及びその水中油型エマルジヨン凍結乾燥による調製方法 Granted JPS60224617A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8405058A FR2561916B1 (fr) 1984-03-30 1984-03-30 Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
FR8405058 1984-03-30

Publications (2)

Publication Number Publication Date
JPS60224617A JPS60224617A (ja) 1985-11-09
JPH0581567B2 true JPH0581567B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-11-15

Family

ID=9302670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60064081A Granted JPS60224617A (ja) 1984-03-30 1985-03-29 経口投与用の製剤及びその水中油型エマルジヨン凍結乾燥による調製方法

Country Status (10)

Country Link
US (1) US4616047A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0159237B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS60224617A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE34078T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU567271B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1233119A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3562555D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8607011A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2561916B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA852168B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
JPS60239417A (ja) * 1984-05-15 1985-11-28 Sankyo Co Ltd エマルシヨン凍結乾燥製剤の製法
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
DE3702029A1 (de) * 1987-01-24 1988-08-04 Basf Ag Waessriges oder pulverfoermiges, wasserdispergierbares praeparat eines in wasser schwerloeslichen pharmazeutischen wirkstoffs und verfahren zu seiner herstellung
IL86892A (en) * 1987-07-08 1993-04-04 Lafon Labor Filter comprising a material obtained by freeze-drying, its preparation and its use, especially in pharmacy
FR2645740B1 (fr) * 1989-04-12 1994-01-28 Fabre Cosmetique Pierre Compositions topiques triphasiques et extemporanement emulsionnables utiles en cosmetologie et/ou dermatologie
US5039540A (en) * 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
WO1991007964A1 (en) * 1989-12-01 1991-06-13 Nippon Shinyaku Co., Ltd. Fat emulsion
JP3074731B2 (ja) * 1989-12-01 2000-08-07 日本新薬株式会社 脂肪乳剤
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
WO1992017162A1 (en) * 1991-04-05 1992-10-15 Warner-Lambert Company Lyophilized emulsion
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
HUT75616A (en) * 1992-03-17 1997-05-28 Pfizer Method for prooucing porous delivery devices
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
EP0663818A4 (en) * 1992-09-03 1996-04-24 Ibah Inc TASTE-COVERING PHARMACEUTICAL SUMMARY AND METHOD FOR PRODUCING THE SAME.
DE4244122C1 (de) * 1992-12-24 1994-06-01 Sanol Arznei Schwarz Gmbh Lyophilisierte, wirkstoffhaltige Emulsion zur intravenösen Applikation
US5382437A (en) * 1993-10-25 1995-01-17 Hunter Research Corporation Frozen liquified gas composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
KR0181252B1 (ko) * 1996-12-31 1999-03-20 박원훈 에멀젼 방법에 의한 다공성 매트릭스형 서방성 제제의 제조방법
GB9702799D0 (en) * 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
AU8977698A (en) * 1997-07-25 1999-02-16 Elan Corporation, Plc A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
DE69935433T2 (de) * 1998-07-30 2007-10-25 Point Biomedical Corp., San Carlos Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
JP2001089398A (ja) * 1999-09-20 2001-04-03 Meiji Seika Kaisha Ltd 経口投与用の凍結乾燥製剤及びその製造方法
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
JP2004521894A (ja) * 2001-01-26 2004-07-22 シェーリング　コーポレイション 胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1353694T1 (sl) * 2001-01-26 2008-06-30 Schering Corp Kombinacije ezetimiba z aspirinom za zdravljenejevaskularnih stanj
CA2434488A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
SK287746B6 (sk) * 2001-01-26 2011-08-04 Schering Corporation Použitie substituovaných azetidinónových zlúčenín na liečenie sitosterolémie
PT1353696E (pt) * 2001-01-26 2007-02-28 Schering Corp Combinações de activador (es) do receptor activado por proliferador do peroxisoma (ppar) e inibidor (es) da absorção de esterol e tratamentos para indicações vasculares
PT1385548E (pt) * 2001-01-26 2007-08-24 Schering Corp Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
CA2437762C (en) * 2001-02-23 2010-08-10 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
EP1392287B8 (en) * 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
NZ531060A (en) * 2001-09-21 2006-06-30 Schering Corp Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2003030872A2 (en) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release
EP1941878A1 (en) 2002-01-10 2008-07-09 Biovail Laboratories International Srl Sedative non-benzodiazepine formulations
JP2005526095A (ja) * 2002-03-20 2005-09-02 エラン ファーマ インターナショナル，リミティド 脆砕性の低い急速溶解投与剤型
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP4776233B2 (ja) * 2002-11-12 2011-09-21 エラン ファーマ インターナショナル，リミティド 摩損しにくくかつプルランを含む速崩壊性固形製剤
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009502A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
US8101226B2 (en) * 2005-03-08 2012-01-24 Nestec S.A. Extruded solid product for use in foodstuffs
CA2618370A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
WO2011109340A1 (en) 2010-03-01 2011-09-09 Nova Southeastern University Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20080031947A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. Orally dissolvable/disintegrable lyophilized dosage forms containing protected
DE102008015366A1 (de) * 2008-03-20 2009-09-24 Merck Patent Gmbh Lyophilisierte Nanoemulsion
EP2359812A1 (en) * 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
WO2011086194A1 (en) 2010-01-18 2011-07-21 Cephalon France Improved oral lysophilisates containing pvp/va
SG10201506873WA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Fast-dissolve dosage forms of 5-ht2c agonists
TR201007613A2 (tr) * 2010-09-16 2012-04-24 Yed�Tepe �N�Vers�Tes� Liyofilize biyopestisit efervesan granül ve üretim yöntemi
CA2819663C (en) 2010-12-02 2019-12-24 Aptalis Pharmatech, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
US20140242177A1 (en) 2011-10-21 2014-08-28 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP2861224A4 (en) 2012-06-15 2015-11-18 Univ Nova Southeastern EPINEPHRINNANOPARTICLES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE USE THEREOF FOR TREATING SUFFERING SUFFERING TO EPINEPHRIN
CA2907770C (en) 2013-03-22 2022-02-15 Nova Southeastern University Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
ES2954361T3 (es) 2017-09-08 2023-11-21 Insignis Therapeutics Inc Métodos de uso de dipivefrina
AU2019361136B2 (en) 2018-10-19 2025-08-14 Nova Southeastern University Sublingual epinephrine compositions including pH-modifying excipients and penetration enhancers and methods for use thereof
US11213484B2 (en) 2019-03-01 2022-01-04 Insignis Therapeutics, Inc. Dipivefrin orally disintegrating tablet formulations
WO2021062374A1 (en) 2019-09-27 2021-04-01 Duke University Tabletization of peptide self-assemblies and methods of making and using the same
GB2638418A (en) * 2024-02-21 2025-08-27 Novumgen Ltd An orodispersible tablet of spironolactone and its process of preparation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2520939A (en) * 1947-01-27 1950-09-05 Inst Divi Thomae Foundation Process of concentrating milk
GB806723A (en) * 1955-09-02 1958-12-31 Ici Ltd New pharmaceutical compositions
US3464834A (en) * 1963-11-18 1969-09-02 Grace W R & Co Freeze-drying ice milk confections
DE2017373A1 (de) * 1969-04-15 1971-04-22 Orsymonde S A , Paris Lyophihsierte Produkte und Ver fahren zu ihrer Herstellung
CH528266A (fr) * 1969-11-26 1972-09-30 Orsymonde Procédé pour la préparation d'une composition lyophilisée à l'usage cosmétique ou hygiénique
ZA738657B (en) * 1973-01-05 1974-10-30 Hoffmann La Roche Emulsions
GB1447988A (en) * 1973-04-03 1976-09-02 Orsymonde Pharmaceutical compositions
US4001944A (en) * 1975-08-25 1977-01-11 Parke, Davis & Company Freeze-drying process
US3961424A (en) * 1975-08-28 1976-06-08 General Foods Corporation Process for freezing coffee extract prior to lyophilization
JPS5296724A (en) * 1976-02-10 1977-08-13 Kyowa Hakko Kogyo Co Ltd Preparation of powdery products
JPS52125615A (en) * 1976-04-09 1977-10-21 Kyowa Hakko Kogyo Co Ltd Method of making powdered products
IL53427A0 (en) * 1976-11-24 1978-01-31 Lilly Co Eli Method of preparing a rapidly dissolving powder of sterile crystalline cefozolin sodium for parenteral administration
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4295280A (en) * 1980-03-17 1981-10-20 American Home Products Corporation Method of obtaining a lyophilized product
US4521975A (en) * 1981-05-04 1985-06-11 Marquest Medical Products, Inc. Lyophilizing and forming biologicals having a predetermined unit dosage
FR2539626B2 (fr) * 1983-01-25 1985-06-21 Lafon Labor Nouveau procede de preparation de formes galeniques utiles notamment en therapeutique, dietetique, cosmetique et diagnostic, et formes obtenues selon ce procede

Also Published As

Publication number Publication date
DE3562555D1 (en) 1988-06-16
ES542483A0 (es) 1986-05-16
US4616047A (en) 1986-10-07
ES8607011A1 (es) 1986-05-16
ZA852168B (en) 1985-11-27
AU567271B2 (en) 1987-11-12
EP0159237B1 (en) 1988-05-11
AU4015385A (en) 1985-10-03
FR2561916B1 (fr) 1987-12-11
FR2561916A1 (fr) 1985-10-04
CA1233119A (en) 1988-02-23
EP0159237A1 (en) 1985-10-23
ATE34078T1 (de) 1988-05-15
JPS60224617A (ja) 1985-11-09

Similar Documents

Publication Publication Date Title
JPH0581567B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP4994039B2 (ja) 脂溶性または疎水性化合物の送達に有用なミセル系
US7569274B2 (en) Impregnated powder improving bioavailability and/or solubility and method of production
ES2592504T3 (es) Preparaciones de liberación controlada
US5891476A (en) Tastemasked pharmaceutical system
US20030077297A1 (en) Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
KR940000231B1 (ko) 2-(2-플루오로-4-비페닐릴)프로피온산을 함유하는 약제학적 조성물의 제조방법
CA2023200A1 (en) A new freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
AU763945B2 (en) Oil-core compositions for the sustained release of hydrophobic drugs
CN101189029A (zh) 含脂相的药物剂型
EP2282722B1 (en) Self-microemulsifying systems incorporated into liquid core microcapsules
EP0152292A2 (en) Acetaminophen gelatin capsules
JP5661630B2 (ja) 弱イオン性化合物の剤形
US20120213855A1 (en) Dosage forms for weakly ionizable compounds
EP1467708A1 (en) New process 1
CN110013467B (zh) 一种固体微粒及其制备方法和含其的药物组合物
CN103142484B (zh) 一种非诺贝特脂质立方液晶固体粉末及其制备方法
MX2007007887A (es) Sistema galenico novedoso para transporte del principio activo, metodo de preparacion y uso.
JP5684440B2 (ja) 組成物および固形製剤
US8435982B2 (en) Pharmaceutical formulation containing lipophilic drugs and milk as a solubilizing/dispensing agent and method for the preparation thereof
Zhang et al. Solubilized formulations
KR101012903B1 (ko) 나노입자 형성을 이용하는 리세드로네이트 경질캡슐
FR2657258A1 (fr) Nouvelle forme unitaire, solide et poreuse comprenant des particules sous forme de perles ainsi que sa preparation.

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term